OTC Drug Advertising Outpaces Rx Direct-To-Consumer Spending At J&J, Schering
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J spent 40% more on OTC ads compared to Rx direct-to-consumer spots during the first nine months. Schering's OTC spending was more than triple expenditures for its prescription consumer advertising due to the Claritin switch.
You may also be interested in...
Pharma Companies Looking To Consumer Divisions To Feed DTC Efforts
Pfizer plans to use Nicorette OTC marketing experience in developing direct-to-consumer advertising for the prescription smoking cessation drug varenicline, currently under development.
Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products
FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation
Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products
FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation